Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553413 | 0.83 | CES2 (0.47) | CES2CES1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8861492 | 0.80 | ESR1 (0.41) | MAPTSMN1; SMN2ALDH1A1TSHRTP53 | |
| SCHEMBL8010216 | 0.80 | CES1 (0.54) | CES2CES1MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL7441502 | 0.79 | CES2 (0.50) | CES2CES1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL11784915 | 0.78 | MAPT (0.43) | CES1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL10739455 | 0.78 | NOS3 (0.42) | CES2CES1L3MBTL1ALDH1A1NOS3 | |
| SCHEMBL9445076 | 0.78 | NOS3 (0.42) | CES2CES1NOS3NOS1LMNA | |
| SCHEMBL7450293 | 0.78 | CES2 (0.51) | CES2CES1MAPTATMALDH1A1 | |
| SCHEMBL2229589 | 0.77 | MAPT (0.41) | CES1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5839905 | 0.77 | HTR3E (0.39) | CES2CES1MAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | claimed |
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| WO-2005105777-A1 | SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-6248752-B1 | Azabicyclooctane compositions and methods for enhancing chemotherapy | SMITH CHARLES DUANE (US) | 2001-06-19 | — | — | US | claimed |
| EP-0465254-B1 | Fused thiophene compounds and uses thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1996-11-13 | — | — | EP | claimed |
| US-5141930-A | Antianxietic drug, antipsychotics and cardiotonic agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-08-25 | — | — | US | claimed |
| US-4684731-A | NEUROLEPTIC, ANTIEMETIC, ANALGESIC | HOFFMANN-LA ROCHE INC. (US) | 1987-08-04 | — | — | US | claimed |
| EP-0037990-B1 | PHENYL QUINOLIZIDINES, CORRESPONDING PHARMACEUTICAL PREPARATIONS, THE PREPARATION OF THE ACTIVE COMPOUNDS AND CORRESPONDING STARTING COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-05 | — | — | EP | claimed |
| EP-0037990-A1 | Phenyl quinolizidines, corresponding pharmaceutical preparations, the preparation of the active compounds and corresponding starting compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-10-21 | — | — | EP | claimed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-108884044-B | Piperidine derivatives | 大塚制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| EP-3395857-B1 | POLYMER CONJUGATE OF SULFOXIDE DERIVATIVE-COORDINATED PLATINUM(II) COMPLEX | NIPPON KAYAKU KK (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-0386640-A2 | Processes for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds and intermediates therefor | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0374095-A2 | Piperidine derivatives | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| US-4665087-A | ANGIOTENSIN-CONVERTING ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1987-05-12 | — | — | US | disclosed |
| US-4435394-A | 3-Sulfonamido-benzophenonimine derivatives useful for treating virus infections | SHIONOGI & CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4056544-A | Anthraquinone compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | CES2 2141/4885CES1 1847/4885MAPT 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.